Grufity logoGrufity logo

Arcturus Therapeutics Holdings Inc. Stock Research

ARCT

15.85USD+0.15(+0.96%)Delayedas of 27 Mar 2023, 02:00 pm

Market Summary

USD15.85+0.15
Delayedas of 27 Mar 2023, 02:00 pm
0.96%

ARCT Stock Price

ARCT RSI Chart

ARCT Valuation

Market Cap

415.9M

Price/Earnings (Trailing)

-2.84

Price/Sales (Trailing)

8.08

Price/Free Cashflow

-2.37

ARCT Price/Sales (Trailing)

ARCT Profitability

Return on Equity

-100.68%

Return on Assets

-49.95%

Free Cashflow Yield

-42.27%

ARCT Fundamentals

ARCT Revenue

Revenue (TTM)

51.5M

Revenue Y/Y

448.58%

Revenue Q/Q

-50.66%

ARCT Earnings

Earnings (TTM)

-146.7M

Earnings Y/Y

34.79%

Earnings Q/Q

-63.55%

Price Action

52 Week Range

11.7031.41
(Low)(High)

Last 7 days

-1.1%

Last 30 days

-10.7%

Last 90 days

-9.0%

Trailing 12 Months

-44.1%

ARCT Financial Health

Current Ratio

3.25

Debt/Equity

0.09

Debt/Cashflow

-12.84

ARCT Investor Care

Shares Dilution (1Y)

0.58%

Diluted EPS (TTM)

-5.56

Peers (Alternatives to Arcturus Therapeutics Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
298.0B
1.4B
-3.25% 8.54%
-148.7
210.43
20.37% -37.45%
279.9B
58.1B
4.88% 1.38%
23.64
4.82
3.30% 2.55%
87.7B
12.2B
9.61% 20.63%
20.21
7.2
-24.26% -46.28%
80.8B
8.9B
6.80% 24.91%
24.32
9.05
17.91% 41.84%
23.5B
1.0B
-5.53% 16.05%
-20.81
22.69
22.88% -32.64%
11.5B
933.0M
2.93% 61.85%
-16.28
12.27
32.93% -67.99%
10.1B
1.9B
-9.77% 22.96%
13.92
5.23
14.88% 52.86%
MID-CAP
4.2B
504.0K
-19.59% 144.55%
-14.38
2.5K
-66.53% -22.12%
2.6B
363.3M
-18.37% -45.49%
-3.74
7.28
3.39% -55.81%
2.6B
204.0M
1.49% -34.21%
-4.68
12.78
13.30% 13.44%
2.3B
12.4M
-15.06% -52.42%
-3.05
181.9
- -27.34%
SMALL-CAP
1.7B
214.2M
4.81% 93.98%
20.42
7.92
52.10% 110.42%
412.2M
151.9M
1.98% -27.23%
-3.44
2.71
96.19% 40.75%
28.6M
-
145.52% 1270.00%
-0.67
19.11
-77.61% 7.22%
3.1M
94.6M
-20.08% -11.44%
-0.01
0.03
34.30% -80.65%

Financials for Arcturus Therapeutics Holdings

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue26.9%51,500,00040,568,00015,476,00012,359,0008,803,000
Operating Expenses-3.0%198,420,000204,502,000211,041,000215,211,000205,092,000
  S&GA Expenses3.8%45,017,00043,389,00042,438,00041,451,00039,679,000
  R&D Expenses-4.8%153,403,000161,113,000168,603,000173,760,000165,413,000
EBITDA--19,845,000----
EBITDA Margin--2.25----
EBT Margin--2.47----
Interest Expenses8.2%755,000698,000684,000684,0001,092,000
Net Income11.4%-146,661,000-165,479,000-198,497,000-203,674,000-196,115,000
Net Income Margin30.2%-2.85-4.08-12.83--
Free Cahsflow-17.5%-175,800,000-149,627,000-146,531,000--
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-12.9%294337342393435
  Current Assets-15.4%247292327379421
    Cash Equivalents-16.2%238283320370414
  Net PPE26.8%11.009.008.006.005.00
Liabilities-11.0%148166157165175
  Current Liabilities-18.2%76.0093.00107100118
  Long Term Debt-13.1%13.0015.0015.0015.0015.00
    LT Debt, Current2.5%28.0027.0024.0022.00-
    LT Debt, Non Current-10.4%32.0036.0039.0041.0042.00
Shareholder's Equity-14.7%146171185228259
  Retained Earnings-8.4%-455-420-398-347-308
  Additional Paid-In Capital1.7%601591583576568
Accumulated Depreciation8.7%5.005.004.004.004.00
Shares Outstanding0.2%26.0026.0026.0026.0026.00
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-17.8%-170,763-145,010-141,132-135,043-99,178
  Share Based Compensation8.8%31,59929,03329,29928,91524,223
Cashflow From Investing-9.1%-5,037-4,617-5,399-3,406-2,985
Cashflow From Financing-126.2%-3971,5151,34048,016210,987

Risks for ARCT

What is the probability of a big loss on ARCT?

100%


Probability that Arcturus Therapeutics Holdings stock will be more than 20% underwater in next one year

100%


Probability that Arcturus Therapeutics Holdings stock will be more than 30% underwater in next one year.

92.3%


Probability that Arcturus Therapeutics Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ARCT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Arcturus Therapeutics Holdings was unfortunately bought at previous high price.

Drawdowns

Returns for ARCT

Cumulative Returns on ARCT

-7.3%


7-Year Cumulative Returns

22.2%


5-Year Cumulative Returns

0.8%


3-Year Cumulative Returns

What are the long-term rolling returns for ARCT?

FIve years rolling returns for Arcturus Therapeutics Holdings.

Annualized Returns

Which funds bought or sold ARCT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-02-21
MACQUARIE GROUP LTD
sold off
-
-4,000
-
-%
2023-02-15
JANE STREET GROUP, LLC
added
174
986,401
1,447,400
-%
2023-02-15
Point72 Middle East FZE
new
-
79,254
79,254
-%
2023-02-15
UNITED CAPITAL FINANCIAL ADVISERS, LLC
sold off
-100
-370,000
-
-%
2023-02-15
Financial Gravity Asset Management, Inc.
new
-
32.00
32.00
-%
2023-02-15
Metropolitan Life Insurance Co/NY
unchanged
-
2,642
23,642
-%
2023-02-15
MetLife Investment Management, LLC
unchanged
-
26,066
209,066
-%
2023-02-15
SALEM INVESTMENT COUNSELORS INC
unchanged
-
696
1,696
-%
2023-02-15
LAZARD ASSET MANAGEMENT LLC
reduced
-7.42
7,000
140,000
-%
2023-02-15
ALLIANCEBERNSTEIN L.P.
unchanged
-
48,688
386,688
-%

1–10 of 44

Latest Funds Activity

Are funds buying ARCT calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ARCT
No. of Funds

Arcturus Therapeutics Holdings News

MarketWatch

Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market.

MarketWatch,
2 days ago

Marketscreener.com

Schedule 13G FIlings of Arcturus Therapeutics Holdings

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
5.46%
1,450,425
SC 13G
Feb 08, 2023
state street corp
8.50%
2,257,846
SC 13G/A
Feb 03, 2023
sumitomo mitsui trust holdings, inc.
5.45%
1,449,060
SC 13G/A
Feb 01, 2023
federated hermes, inc.
16.00%
4,239,554
SC 13G/A
Jan 31, 2023
blackrock inc.
7.1%
1,884,885
SC 13G/A
Apr 11, 2022
state street corp
12.20%
3,217,957
SC 13G/A
Feb 14, 2022
nikko asset management americas, inc.
5.15%
1,357,472
SC 13G
Feb 14, 2022
federated hermes, inc.
14.02%
3,694,929
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
0.0%
15,039
SC 13G/A
Feb 11, 2022
state street corp
7.80%
2,056,074
SC 13G

ARCT Fair Value

Arcturus Therapeutics Holdings fair value in different scenarios

The table shows the Fair Value estimates for Arcturus Therapeutics Holdings for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

1.35

-91.48%

1.54

-90.28%

1.96

-87.63%

5.02

-68.33%

8.99

-43.28%
Current Inflation

1.34

-91.55%

1.51

-90.47%

1.89

-88.08%

4.54

-71.36%

7.95

-49.84%
Very High Inflation

1.33

-91.61%

1.48

-90.66%

1.80

-88.64%

3.98

-74.89%

6.75

-57.41%

Historical Arcturus Therapeutics Holdings Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Arcturus Therapeutics Holdings

View All Filings
Date Filed Form Type Document
Mar 17, 2023
8-K
Current Report
Mar 08, 2023
4
Insider Trading
Feb 10, 2023
SC 13G/A
Major Ownership Report
Feb 10, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
SC 13G
Major Ownership Report
Feb 08, 2023
SC 13G/A
Major Ownership Report
Feb 03, 2023
SC 13G/A
Major Ownership Report
Feb 01, 2023
SC 13G/A
Major Ownership Report
Jan 31, 2023
SC 13G/A
Major Ownership Report
Dec 30, 2022
EFFECT
EFFECT

Latest Insider Trading transactions for ARCT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-06
Chivukula Pad
sold
-80,350
16.07
-5,000
chief scientific officer & coo
2022-12-15
Marquet Magda
bought
39,996
18.00
2,222
-
2022-11-23
Payne Joseph E
bought
82,550
16.51
5,000
president and ceo
2022-08-15
SASSINE ANDY
acquired
19,672
18.4195
1,068
chief financial officer
2022-01-04
Chivukula Pad
sold
-324,000
40.00
-8,100
chief scientific officer & coo
2021-12-16
Chivukula Pad
sold
-145,328
40.0021
-3,633
chief scientific officer & coo
2021-12-08
Chivukula Pad
sold
-254,680
40.00
-6,367
chief scientific officer & coo
2021-11-01
Chivukula Pad
sold
-444,100
44.41
-10,000
chief scientific officer & coo
2021-10-01
Chivukula Pad
sold
-443,600
44.36
-10,000
chief scientific officer & coo
2021-09-01
Chivukula Pad
sold
-558,600
55.86
-10,000
chief scientific officer & coo

1–10 of 35

About Arcturus Therapeutics Holdings

ARCT Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]    
Revenue$ 13,369$ 2,437$ 45,706$ 6,565
Operating expenses:    
Research and development, net37,68845,398120,770141,127
General and administrative12,48810,86034,21130,645
Total operating expenses50,17656,258154,981171,772
Loss from operations(36,807)(53,821)(109,275)(165,207)
Gain (loss) from equity-method investment (250)(515)670
Gain from foreign currency1,8625063,237923
Finance expense, net(321)(519)(1,445)(1,397)
Net loss$ (35,266)$ (54,084)$ (107,998)$ (165,011)
Net loss per share, basic$ (1.33)$ (2.05)$ (4.09)$ (6.27)
Net loss per share, diluted$ (1.33)$ (2.05)$ (4.09)$ (6.27)
Weighted-average shares outstanding, basic26,46726,33826,42326,302
Weighted-average shares outstanding, diluted26,46726,33826,42326,302
Comprehensive loss:    
Net loss$ (35,266)$ (54,084)$ (107,998)$ (165,011)
Comprehensive loss$ (35,266)$ (54,084)$ (107,998)$ (165,011)

ARCT Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 237,676$ 370,492
Accounts receivable2,0443,367
Prepaid expenses and other current assets6,9605,102
Total current assets246,680378,961
Property and equipment, net11,3475,643
Operating lease right-of-use asset, net33,5195,618
Equity-method investment 515
Non-current restricted cash2,0812,077
Total assets293,627392,814
Current liabilities:  
Accounts payable17,96210,058
Accrued liabilities25,52923,523
Current portion of long-term debt27,70222,474
Deferred revenue4,65643,482
Total current liabilities75,84999,537
Deferred revenue, net of current portion5,17919,931
Long-term debt, net of current portion32,03840,633
Operating lease liability, net of current portion31,2184,502
Other non-current liabilities3,676 
Total liabilities147,960164,603
Stockholders’ equity  
Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,492 at September 30, 2022 and 26,372 at December 31, 20212626
Additional paid-in capital601,129575,675
Accumulated deficit(455,488)(347,490)
Total stockholders’ equity145,667228,211
Total liabilities and stockholders’ equity$ 293,627$ 392,814